AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...
SLE is an autoimmune condition causing symptoms such as joint swelling AstraZeneca has received approval from the US Food and ...
The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
The FDA has approved a self-administered autoinjector form of anifrolumab for the treatment of systemic lupus erythematosus, ...
Precision immunotherapy strategies are redefining systemic lupus erythematosus treatment by targeting immune pathways. Read ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
Weight-based dosing misses accounting for factors such as chronic kidney disease or chronic transaminitis, which could ...
Patients with systemic lupus erythematosus have higher risks for mortality and complications than control individuals; Black ...
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for ...
That’s what the autoimmune disease lupus does, 1 and when it strikes, it can cause significant symptoms, including extreme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results